Other News To Note

• BioLineRx Ltd., of Jerusalem, said a recent analysis of data from its Phase IIb EAGLE trial testing orally available GABA-enhanced antipsychotic BL-1020 in schizophrenia indicated that the drug demonstrated a significant increase in efficacy at improving cognitive impairment associated with the condition, as compared to the original analysis of the study.